11:03 AM
 | 
Nov 17, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALK's tree allergy SLIT meets in Phase III for birch pollen allergy

In September, ALK-Abello A/S (CSE:ALK-B) reported data from a Phase III trial in 634 patients ages 12-65 with birch pollen allergic rhinitis and/or conjunctivitis showing that tree allergy sublingual immunotherapy (SLIT) met the primary endpoint of reducing daily total combined score vs. placebo (p<0.0001). Specifically,...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >